Adding one year of treatment with durvalumab to BCG can extend the time that patients live without disease recurrence.
Non-Muscle Invasive Urothelial Carcinoma
Advertisement
Latest News
Dr. Gomella and Ambinder provide a comprehensive overview of the growing and changing treatment landscape for NMIBC.
Dr. Tyson discusses real-world decision-making around bladder-sparing options for BCG-unresponsive NMIBC.
Previous research has shown that BLC can provide improved detection rates, mainly for high-risk disease and invasive tumors.
Noah Hahn, MD, gives an overview of durvalumab with intravesical gemcitabine and docetaxel for BCG-unresponsive NMIBC.
This new research shows no link between patient BMI and NMIBC recurrence, stage progression, or grade progression.
Sasanlimab is being further studied in combination with other antibody drug conjugate treatments in advanced solid tumors.
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
Dr. Evan Kovac speaks about his pioneering work with extended reality display technology in urologic surgery and education.
Dr. Canes discusses the formation of the WellPrept delivery platform and how it aims to boost patient education.
Mohummad Siddiqui, MD, discusses his work with the Commission on Cancer and their development on standards of care.
John P. Sfakianos, MD, discusses the history and use of ctDNA in the GU oncology field.
Dr. Sandoval chats with David Ambinder, MD, on the upstaging of cT1b and cT2 tumors to pT3a.
Maximizing Benefits and Minimizing Harm: Reviewing AUA Guidelines on Prostate Cancer Early Detection
Dr. Salami explains how updated guideline approaches shared decision-making in higher-risk groups.Advertisement
Section Editor
Sia Daneshmand, MDEditor | Professor of Urology and Medicine (Oncology) at the University of Southern California
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.